Clinical trial
An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Participated in Study MRA012JP
NCT00144547 is registered in ClinicalTrials.gov with Chugai Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Participated in Study MRA012JP
- Lead sponsor
- Chugai Pharmaceutical
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 30, 2004
- Completion date
- June 30, 2009
- Enrollment
- 241 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
rheumatoid arthritis